Zyversa Therapeutics Stock Market Value
| ZVSA Stock | 1.14 0.01 0.87% |
| Symbol | ZyVersa |
ZyVersa Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ZyVersa Therapeutics. If investors know ZyVersa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ZyVersa Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 491.97 | Return On Assets (0.25) | Return On Equity (1.52) |
The market value of ZyVersa Therapeutics is measured differently than its book value, which is the value of ZyVersa that is recorded on the company's balance sheet. Investors also form their own opinion of ZyVersa Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is ZyVersa Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ZyVersa Therapeutics' market value can be influenced by many factors that don't directly affect ZyVersa Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ZyVersa Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ZyVersa Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ZyVersa Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
ZyVersa Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to ZyVersa Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of ZyVersa Therapeutics.
| 05/26/2024 |
| 11/22/2024 |
If you would invest 0.00 in ZyVersa Therapeutics on May 26, 2024 and sell it all today you would earn a total of 0.00 from holding ZyVersa Therapeutics or generate 0.0% return on investment in ZyVersa Therapeutics over 180 days. ZyVersa Therapeutics is related to or competes with Cns Pharmaceuticals, Immix Biopharma, Hepion Pharmaceuticals, and Zura Bio. ZyVersa Therapeutics is entity of United States More
ZyVersa Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure ZyVersa Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess ZyVersa Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.14) | |||
| Maximum Drawdown | 78.93 | |||
| Value At Risk | (10.36) | |||
| Potential Upside | 9.17 |
ZyVersa Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for ZyVersa Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as ZyVersa Therapeutics' standard deviation. In reality, there are many statistical measures that can use ZyVersa Therapeutics historical prices to predict the future ZyVersa Therapeutics' volatility.| Risk Adjusted Performance | (0.09) | |||
| Jensen Alpha | (0.99) | |||
| Total Risk Alpha | (2.15) | |||
| Treynor Ratio | 0.6005 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of ZyVersa Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
ZyVersa Therapeutics Backtested Returns
ZyVersa Therapeutics shows Sharpe Ratio of -0.13, which attests that the company had a -0.13% return per unit of risk over the last 3 months. ZyVersa Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out ZyVersa Therapeutics' Standard Deviation of 8.8, mean deviation of 4.67, and Market Risk Adjusted Performance of 0.6105 to validate the risk estimate we provide. The firm maintains a market beta of -1.91, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning ZyVersa Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, ZyVersa Therapeutics is expected to outperform it. At this point, ZyVersa Therapeutics has a negative expected return of -1.05%. Please make sure to check out ZyVersa Therapeutics' total risk alpha, as well as the relationship between the skewness and day median price , to decide if ZyVersa Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.70 |
Good predictability
ZyVersa Therapeutics has good predictability. Overlapping area represents the amount of predictability between ZyVersa Therapeutics time series from 26th of May 2024 to 24th of August 2024 and 24th of August 2024 to 22nd of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of ZyVersa Therapeutics price movement. The serial correlation of 0.7 indicates that around 70.0% of current ZyVersa Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.7 | |
| Spearman Rank Test | 0.65 | |
| Residual Average | 0.0 | |
| Price Variance | 0.24 |
ZyVersa Therapeutics lagged returns against current returns
Autocorrelation, which is ZyVersa Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting ZyVersa Therapeutics' stock expected returns. We can calculate the autocorrelation of ZyVersa Therapeutics returns to help us make a trade decision. For example, suppose you find that ZyVersa Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
ZyVersa Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If ZyVersa Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if ZyVersa Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in ZyVersa Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
ZyVersa Therapeutics Lagged Returns
When evaluating ZyVersa Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of ZyVersa Therapeutics stock have on its future price. ZyVersa Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, ZyVersa Therapeutics autocorrelation shows the relationship between ZyVersa Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in ZyVersa Therapeutics.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ZyVersa Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ZyVersa Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zyversa Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zyversa Therapeutics Stock:Check out ZyVersa Therapeutics Correlation, ZyVersa Therapeutics Volatility and ZyVersa Therapeutics Alpha and Beta module to complement your research on ZyVersa Therapeutics. For information on how to trade ZyVersa Stock refer to our How to Trade ZyVersa Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
ZyVersa Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.